CN115666615A - 用于治疗冠状病毒感染的化合物 - Google Patents

用于治疗冠状病毒感染的化合物 Download PDF

Info

Publication number
CN115666615A
CN115666615A CN202180018709.2A CN202180018709A CN115666615A CN 115666615 A CN115666615 A CN 115666615A CN 202180018709 A CN202180018709 A CN 202180018709A CN 115666615 A CN115666615 A CN 115666615A
Authority
CN
China
Prior art keywords
day
compound
cov
substituted
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018709.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·费南德斯·索萨-法罗
P·阿维莱斯·马林
A·洛萨达·冈萨雷斯
S·夫迪奥·穆尼奥斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN115666615A publication Critical patent/CN115666615A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202180018709.2A 2020-03-02 2021-03-02 用于治疗冠状病毒感染的化合物 Pending CN115666615A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP20382152.5 2020-03-02
EP20382152 2020-03-02
EP20382192.1 2020-03-13
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382266.3 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382816.5 2020-09-16
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382815 2020-09-16
PCT/EP2021/055137 WO2021175826A1 (en) 2020-03-02 2021-03-02 Compounds for use in the treatment of coronavirus infection

Publications (1)

Publication Number Publication Date
CN115666615A true CN115666615A (zh) 2023-01-31

Family

ID=74797953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018709.2A Pending CN115666615A (zh) 2020-03-02 2021-03-02 用于治疗冠状病毒感染的化合物

Country Status (17)

Country Link
US (1) US20230158102A1 (https=)
EP (1) EP4114436A1 (https=)
JP (1) JP2023517295A (https=)
KR (1) KR20220151181A (https=)
CN (1) CN115666615A (https=)
AU (1) AU2021232534A1 (https=)
BR (1) BR112022017008A2 (https=)
CA (1) CA3169791A1 (https=)
CL (1) CL2022002398A1 (https=)
CO (1) CO2022014115A2 (https=)
IL (1) IL296066A (https=)
MX (1) MX2022010922A (https=)
PE (1) PE20231069A1 (https=)
PY (1) PY2117315A (https=)
TW (1) TW202144380A (https=)
UY (1) UY39108A (https=)
WO (1) WO2021175826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004985A1 (en) * 1989-09-29 1991-04-18 Pharma Mar S.A. Dehydrodidemnin b
CN1901921A (zh) * 2003-11-10 2007-01-24 香港大学 用于治疗sars冠状病毒感染或其它相关感染的黄芩苷和其衍生物
CN102256994A (zh) * 2008-12-19 2011-11-23 法马马有限公司 抗癌化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004985A1 (en) * 1989-09-29 1991-04-18 Pharma Mar S.A. Dehydrodidemnin b
CN1901921A (zh) * 2003-11-10 2007-01-24 香港大学 用于治疗sars冠状病毒感染或其它相关感染的黄芩苷和其衍生物
CN102256994A (zh) * 2008-12-19 2011-11-23 法马马有限公司 抗癌化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEJANDRO LOSADA等: "Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin", SCI REP, vol. 6, 7 October 2016 (2016-10-07) *
BING ZHOU等: "The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha", J VIROL, vol. 82, no. 14, 30 April 2008 (2008-04-30) *

Also Published As

Publication number Publication date
KR20220151181A (ko) 2022-11-14
UY39108A (es) 2021-09-30
JP2023517295A (ja) 2023-04-25
PY2117315A (es) 2022-05-10
MX2022010922A (es) 2022-09-29
PE20231069A1 (es) 2023-07-17
AU2021232534A1 (en) 2022-10-06
TW202144380A (zh) 2021-12-01
US20230158102A1 (en) 2023-05-25
BR112022017008A2 (pt) 2022-10-11
CO2022014115A2 (es) 2022-11-18
IL296066A (en) 2022-11-01
CL2022002398A1 (es) 2023-06-30
EP4114436A1 (en) 2023-01-11
CA3169791A1 (en) 2021-09-10
WO2021175826A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7671305B2 (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
US20230295236A1 (en) Compounds for use in inflammatory conditions
TWI750051B (zh) 用於預防或治療嚴重急性呼吸綜合症冠狀病毒２感染疾病的組合物
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
JP2023526754A (ja) Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法
KR20220150348A (ko) 코로나바이러스의 치료에 조합하여 사용하기 위한 pld
CN115666615A (zh) 用于治疗冠状病毒感染的化合物
US20230226066A1 (en) Compounds for the treatment of viral infections
US20220233480A1 (en) Use of angiotensin ii type 2 receptor agonist
EA050340B1 (ru) Соединения для применения в лечении коронавирусной инфекции
EA050436B1 (ru) Соединения для применения при воспалительных состояниях
HK40081689A (en) New use of angiotensin ii type 2 receptor agonist
HK40081689B (en) New use of angiotensin ii type 2 receptor agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination